This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Parkhurst, M. R. Articles by Rosenberg, S. A. Search for Related Content PubMed PubMed Citation Articles by Parkhurst, M. R. Articles by Rosenberg, S. A.

Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells

Authors' Affiliations: ¹ Surgery Branch, National Cancer Institute/NIH, Bethesda, Maryland and ² University of California-Los Angeles Medical School, Los Angeles, California

Requests for reprints: Maria R. Parkhurst, Surgery Branch, National Cancer Institute/NIH, Building CRC, Room 4-5744, 9000 Rockville Pike, Bethesda, MD 20892. Phone: 301-435-3026; Fax: 301-435-5167; E-mail: Maria_Parkhurst{at}nih.gov.

Purpose: Carcinoembryonic antigen (CEA) is a tumor-associated protein expressed on a variety of adenocarcinomas. To develop an immunotherapy for patients with cancers that overexpress CEA, we isolated and genetically modified a T-cell receptors (TCRs) that specifically bound a CEA peptide on human cancer cells.

Experimental Design: HLA-A2.1 transgenic mice were immunized with CEA:691-699. A CEA-reactive TCR was isolated from splenocytes of these mice and was genetically introduced into human peripheral blood lymphocytes via RNA electroporation or retroviral transduction. Amino acid substitutions were introduced throughout the complementarity determining regions (CDR1, CDR2, and CDR3) of both TCR and β chains to improve recognition of CEA.

Results: Murine lymphocytes bearing the CEA-reactive TCR specifically recognized peptide-loaded T2 cells and HLA-A2.1⁺ CEA⁺ human colon cancer cells. Both CD8⁺ and CD4⁺ human lymphocytes expressing the murine TCR specifically recognized peptide-loaded T2 cells. However, only gene-modified CD8⁺ lymphocytes specifically recognized HLA-A2.1⁺ CEA⁺ colon cancer cell lines, and tumor cell recognition was weak and variable. We identified two substitutions in the CDR3 of the chain that significantly influenced tumor cell recognition by human peripheral blood lymphocytes. One substitution, T for S at position 112 (S112T), enhanced tumor cell recognition by CD8⁺ lymphocytes, and a second dually substituted receptor (S112T L110F) enhanced tumor cell recognition by CD4⁺ T cells.

Conclusions: The modified CEA-reactive TCRs are good candidates for future gene therapy clinical trials and show the power of selected amino acid substitutions in the antigen-binding regions of the TCR to enhance desired reactivities.